Microscopic haematuria in patients with rheumatoid arthritis on d-penicillamine.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to D Barraclough.
Explore the source record for details and available documents.
In 1974 Shulman described two patients who had a scleroderma-like thickening of the skin in association with eosinophilia. Biopsies revealed striking thickening of the fascia between the subcutaneous tissue and muscle, with intense infiltration of plasma cells and lymphocytes. There was no evidence of myositis or of the visceral manifestations of systemic sclerosis. Reports of similar patients have since appeared; we report a further patient thought to have this condition.
The difficulties encountered in administering D-penicillamine to 40 patients with rheumatoid arthritis (RA) over a six to 24 month period are recorded. Side-effects were frequent. Proteinuria occurred in 13 patients (33%) mainly in the fourth to the sixth month. Renal biopsies were performed in six patients and all showed light microscopy abnormalities. Electron microscopy performed in five patients revealed subepithelial deposits in all and in addition some had mesangial and subendothelial deposits. Seven patients (17.5%) developed eight episodes of thrombocytopaenia which was quickly reversed on cessation of treatment or reduction in dosage. On the positive side, there was significant improvement in most parameters of disease activity at six, 12 and 18 months compared to the pretreatment levels, but the results at two years were less impressive. Reduction in steroid dosage was considerable and was greater than half the mean pretreatment dose after two years but the absence of a control group makes the full significance of these uncertain. Patients on high and low dosage regimens were compared over a 12 month period of treatment. Although the differences were not statistically significant, withdrawals and side-effects were less frequent in the low dose group.
Explore the source record for details and available documents.
Laboratory investigations have been perhaps the most important factor in the development of our understanding and classification of rheumatic diseases. Provided they are used and interpreted appropriately, they can assist considerably in the diagnosis and management of these diseases. They are an important adjunct to clinical findings, but not a substitute for them.
Juvenile rheumatoid arthritis (JRA) has become the predominant rheumatic disease of childhood. In a survey of 292 children referred to a rheumatic disease unit over a 5-year period, 94 had JRA and only three had rheumatic fever. At follow-up, of the children with JRA, 70% were found to be in remission with little or no functional disability. Febrile onset of JRA or onset before six years of age were worse prognostic features than pauciarticular or polyarticular onset of occurrence after six years of age. Of 28 children who had either growing pains or psychogenic rheumatism, two were subsequently found to have chondromalacia patellae. None of the other children in this group for whom follow-up information was available had developed organic disease.
Still's disease can no longer be considered a rare disorder. Although the onset usually follows one of several definable patterns, some patients may present with features at variance with classical descriptions of the disease. Four such patients are described to illustrate some of the diagnostic problems which may arise.
Thirty-three per cent of patients with psoriatic spondyloarthropathy referred to a rheumatic disease unit were found to have radiological sacroiliitis. The majority of these patients had definite or probable spondylitis according to the New York criteria. Abnormal sacroiliac uptake of 99mTcPP on bone scan correlated well with the radiological finding of sacroiliitis. In addtion, eight patients with normal radiographs had an abnormal uptake of radionuclide over the sacroiliac joints, indicating sacroiliitis. Patients with sacroiliitis tended to have more severe psoriasis. Sacroiliitis occurred in association with all of the patterns of peripheral joint involvement which may occur in psoriatic arthritis. Although the HLA antigen B27 was present in only 21 percent of the total group and in 33 percent of those with sacroiliitis, 8 out of 10 with this antigen had sacroiliitis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The sera of 40 patients with severe progressive rheumatoid arthritis were examined for the presence of soluble immune complexes before penicillamine therapy was started, and again after treatment for a mean period of 14-4 months. The methods used were radiobioassay (macrophage uptake), C1q-binding capacity, and precipitation by 4% polyethylene glycol. Before treatment the sera of 37 patients showed significantly enhanced uptake of 125I-labelled aggregated human IgG by guinea pig macrophages. Treatment produced significant falls in mean erythrocyte sedimentation rate, differential agglutination titre, and serum IgG and IgM levels, and enhancing complexes (EC) decreased or disappeared in 20 patients. In 9 patients EC changed to inhibiting complexes, and in 8 EC levels were unchanged. In 6 of 8 patients with cutaneous vasculitis initially, both lesions and EC disappeared. The total protein and the IgG and IgM precipitated from patients' sera by 4% polyethylene glycol fell significantly on treatment. Antinuclear antibody titres were unchanged by penicillamine, and 3 patients acquired these antibodies during treatment. These findings suggest that penicillamine treatment in rheumatoid arthritis reduces the level of circulating soluble immune complexes in which IgM rheumatoid factor is a component.
Serum and urinary gold levels were monitored in 18 patients previously treated with gold salts for rheumatoid arthritis and the effects of D-penicillamine studied. There was no statistically significant change in urinary gold levels on D-penicillamine therapy although there were some individual variations. Serum gold levels fell during D-penicillamine therapy but the rates of fall did not differ from those seen in patients not treated. In vitro studies on protein binding of gold salts suggest that a high affinity exists between gold salts and albumin with low levels of unbound gold even at concentrations far exceeding those seen in vivo. These preliminary results suggest that at therapeutic levels only small amounts of gold are available for chelation by penicillamine. It is concluded that penicillamine at low dosage is an unreliable chelator of gold salts in vivo and its use in the management of gold toxicity remains speculative.
Faecal haem-porphyrin assay by the HemoQuant method has many practical advantages over the well-validated, radiochromium (51Cr-tagged red cell) method for measuring gastrointestinal blood loss. Because haem may be absorbed but the chronic ion is not, the two measures were directly compared in low-grade bleeding from the proximal gastrointestinal tract. Blood loss was measured by both methods simultaneously in 40 patients with osteoarthritis before and during medication with aspirin preparations. Mean (geometric) daily blood loss before aspirin usage measured 0.60 mL radiochromium (range 0.13-1.62) and 0.47 mL (0.14-1.40) by HemoQuant (P = 0.042). On aspirin, bleeding rose to 1.57 mL/day (0.43-4.85) by radiochromium and to 0.72 mL/day (0.23-3.0) by HemoQuant (P < 0.0001). The two measures correlated well, r = 0.847 (P << 0.0001), but the regression coefficient was 0.417, reflecting the lower estimates of bleeding by HemoQuant. In four normal subjects who ingested 51Cr-labelled red cells (26-41 mL) over 3 days, recovery of 51Cr was complete (103 +/- 2%, +/- s.e.), but recovery of haem-porphyrins was only 63 +/- 13% (P = 0.01), presumably because of absorption of haem. Although faecal haem-porphyrin assay is of considerable clinical utility, it is a quantitative index rather than an absolute measure when low amounts of bleeding originate from the proximal gastrointestinal tract.
We compared auranofin (AF) in a single blind multi-centre study with gold sodium thiomalate and D-penicillamine in the treatment of rheumatoid arthritis. Adult patients with disease duration 6-60 months without previous treatment with gold salts with persistent active disease, were included. Thirty-nine patients, 13 in each treatment group, have so far been entered. Cumulative toxicity data and some results of efficacy assessments in those completing 9 months of treatment are presented. AF is very well tolerated, judgment concerning efficacy must await the end of the trial.